Skip to content
i2E
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
Search

2020: Something good emerging out of the bad

Get in Touch

By Scott Meacham

When I was a boy, I learned from my grandparents that when something bad happened, that something good would come out of it. I have been thinking about that lesson over the last few day, ever since the first doses of COVID-19 vaccine began shipping and healthcare workers and others began receiving shots.

This has been a really bad year. Millions of in our country are sick with Covid-19. Hundreds of thousands have died. The economic devastation to families, businesses, and states is terrible, and we are not past it yet. So believe me, I am no Pollyanna about the conditions we face and how steep a hill we have yet to climb.

But in all this bad, I see extraordinary good. We have vaccines developed with demonstrated with a previously unheard of efficacy and safety in human trials that have been brought to the market in less than a year. Think about what that means for innovation and inspiration in the biotech industry going forward — not to mention what it means for the health and safety of all.

Pfizer, one of the world’s oldest and largest biotechnology companies, is shipping the first COVID-19 vaccine. There is something fitting about Pfizer being the first. Founded as a startup by immigrants in New York in 1849, Pfizer developed fermentation technology that enabled the mass production of citric acid. During World War II, Pfizer extended that technology for the mass production of penicillin to treat Allied soldiers. With this legacy, it seems natural that Pfizer is among the first to mass produce and distribute the vaccine for COVID-19

Moderna, the second biotech now approved to distributed COVID-19 vaccine in the United States, is a ten-year-old biotech based in Cambridge, MA. Moderna is advancing messenger RNA therapeutics and vaccines to create a new class of medicines.

These companies have achieved amazing results by bringing a vaccine to market in less than twelve months for a disease that was virtually unknown a year ago. However, they invested in the foundational research on which they built their vaccines long before this pandemic. They know how to conduct reputable, scientific trials. Over centuries, Pfizer has mastered large-scale production. Modern is a model of collaboration with strategic partners. This is a David and Goliath story where both the giant and the bold upstart win.

I have often written in this column about the potential of commercialized research to both save lives and create jobs. Here we have Pfizer, more than 170 years in existence and continuing to produce blockbuster therapies, and then we have Moderna, at ten years and near-startup status in biotech, scaling up to deliver more than 100 million doses of the vaccine around the world in early 2021.

With the examples of Pfizer and Moderna, let us be reminded of the potential of biotechnology research and commercialization that exists right here in Oklahoma. With our internationally recognized research institutions and the track record of our state’s serial entrepreneurs in commercializing promising medical technology, we too have the potential to develop and commercialize therapies that can change the world.

Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state support from the Oklahoma Center for the Advancement of Science and Technology and is an integral part of Oklahoma’s Innovation Model. Contact Meacham at [email protected].

More News

Loading...
Blog, Featured, News
12.16.24

MidAmerica and i2E Announce Award Winners

Read more
Blog, Featured, News
11.21.24

i2E & Plains Ventures Surpasses $100M Milestone in Total Investments

Read more
Blog
09.30.24

i2E Receives 2024 Excellence in Economic Development Award from IEDC

Read more
Blog
06.18.24

Bridge2 Demo Day Returns, Highlighting Promising Oklahoma Startups

Read more
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
05.13.24

Student Entrepreneurs Triumph at 20th Anniversary Entrepreneur’s Cup, Winning $158,000 in Prizes

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.24.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Jessica Kinsey

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Nathan Fountain

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Srijita Ghosh

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.18.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – MaxQ

Read more
Blog, i2E
01.30.24

i2E Celebrates Success of Inaugural Bridge2 Demo Day

Read more
Blog, i2E, News
12.18.23

i2E and MidAmerica Industrial Park announce award winners for high school entrepreneurship program

Read more
Blog, i2E
12.13.23

Entrepreneur’s Cup Marks 20 Years: Reimagined Competition and Brand – Same Entrepreneurial Spirit

Read more
i2E

Oklahoma City Office

201 Robert S Kerr Ave, Suite 600
Oklahoma City, OK 73102
+1 (405) 235.2305

Tulsa Office

12 N. Cheyenne Ave, Suite 112
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources
  • Funding
  • Venture Advisory

© 2025 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram Youtube

Programs

  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Events
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E